Exact sciences corporation stock.

May 9, 2023 · MADISON, Wis., May 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS ), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of ... Stock Information · Financial Information · SEC Filings · Quarterly Results · Analyst Coverage ... © Exact Sciences Corporation – 5505 Endeavor Lane - Madison, WI ...Exact Sciences Company Info. EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non ..."Exact Sciences Corporation (NASDAQ:EXAS) is a cancer diagnostics company whose flagship product is Cologuard, a stool-based screening test for colon cancer. The stock declined because financial ...

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present new data supporting the company's research in early cancer ...The Exact Sciences pipeline is expanding at a rapid pace. We’re taking the same innovative problem-solving approach that resulted in the multitarget stool DNA test (Cologuard) to tackle a wide array of cancer screening challenges.

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is ...Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2023 financial results after ...

May 15, 2023 · On Nov 8, 2019, Exact Sciences completed the acquisition of Genomic Health for a value of approximately $2.8 billion. Prior to merger, Genomic Health was a prominent provider of genomic-based ... In summary, the author projects Exact Sciences Corporation as a "buy" at a 1-year price target of $150 (+13% upside) with strong further upside through 2023. Photo by peterschreiber.media/iStock ...Stocks Exact Sciences Corp Exact Sciences Corp EXAS Morningstar Rating Unlock Stock XNAS Rating as of Nov 30, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns...Share Price. EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the ...

EXACT Sciences Corp. Aktie Profil. Die EXACT Sciences Corp. Aktie wird unter der ISIN US30063P1057 an den Börsen Frankfurt, Düsseldorf, München, Stuttgart, Berlin, Hannover, NASDAQ, Moskau ...

May 18, 2023 · On May 17, 2023, Exact Sciences Corporation (NASDAQ:EXAS) stock closed at $78.63 per share. One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was 18.54%, and its shares gained 45.61% of ...

The current analyst firm consensus has Exact Sciences losing just over $3.50 a share in FY2022 on 16% year-over-year revenue growth with sales just over $2.05 billion for the fiscal year. They ...Whether you’re a solo small business owner or an administrative assistant at a huge multinational corporation, it can be important to make sure your office is stocked with the right tools to get the job done. Use these tips to choose the ri...May 9, 2023 · MADISON, Wis., May 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $602.5 million for the first quarter ended March 31, 2023, compared to $486.6 million for the same period of 2022. Stocks United States EXAS Overview Stock Screener Earnings Calendar Sectors Nasdaq | EXAS U.S.: Nasdaq Exact Sciences Corp. Watch NEW Set a price target alert Premarket Last Updated: Nov... Dec 4, 2023 · Exact Sciences Corporation‘s (EXAS Quick Quote EXAS - Free Report) shares have surged 35.4% year to date against the industry’s decline of 21.2%. The Medical sector has dropped 8.1% in the ...

The Exact Sciences Corp (NASDAQ: EXAS) stock price reached the ceiling this week, with shares gaining a sizable 16.38% over the past five days.. Most of that value climb came yesterday, with the ...EXACT Sciences News: This is the News-site for the company EXACT Sciences on Markets Insider Indices Commodities Currencies StocksMADISON, Wis., Feb. 21, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $553.0 million for the fourth quarter of 2022 and $2,084.3 million for the full year of 2022, both ended Dec. 31, 2022.16 brokers have issued twelve-month price targets for Exact Sciences' stock. Their EXAS share price targets range from $73.00 to $130.00. On average, they expect the company's share price to reach $96.56 in the next year. This suggests a possible upside of 44.1% from the stock's current price. View analysts price targets for EXAS or view top ...EXAS is the ticker symbol for Exact Sciences Corporation, a company that provides cancer screening and diagnostic test products. The stock price, news, quote, history and performance outlook of EXAS are shown on Yahoo Finance. See the latest earnings …Exact Sciences EXAS Operating Losses;.Another 70% to Fall!! The EXAC chart has been a downtrend from $130 to $40 with a High VOLUME. The stock is making new bottoms while insiders and the executive team have constantly been selling at any price! The stock is down 70% from its high of $137!

Feb 3, 2023 · Achieving some impressive results. Exact Sciences has already done well in growing its business. Sales of $1.8 billion in 2021 were double what the company generated in 2019 ($876 million). Exact Sciences' valuation has been plummeting. In 2022, shares of Exact Sciences fell 36%, underperforming the S&P 500, which declined by 19%. Exact Sciences isn't near its 52-week low of $29.27 ...

Exact Sciences Corp. Presents Multiple Studies At San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients CI Nov. 29: Transcript : Exact Sciences Corporation Presents at The 6th Annual Evercore ISI HealthCONx Conference, Nov-29-2023 12:30 PMintraday 1w 1m 6m ytd 1y 3y 5y max Mountain-Chart Compare with Compare with up to 5 Stocks On Wednesday 11/29/2023 the closing price of the EXACT …Exact Sciences' valuation has been plummeting. In 2022, shares of Exact Sciences fell 36%, underperforming the S&P 500, which declined by 19%. Exact Sciences isn't near its 52-week low of $29.27 ...The company's screening revenue (including laboratory services for Cologuard) saw an even more significant growth of 45% year over year. While Exact Sciences remains unprofitable, there was major ...Exact Sciences Corporation analysts consensus, targets, ratings and recommendations | Nasdaq: EXAS | NasdaqExact Sciences Corp. (Nasdaq: EXAS) (the "Company"), a leading provider of cancer screening and diagnostic tests, today announced that on February 23, 2023 it entered into a privately negotiated ...Exact Sciences Corp. (EXAS) will release its next earnings report on Feb 20, 2024. In the last quarter Exact Sciences Corp. reported -$0.471 EPS in relation to $0 expected by the market. ... Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including ...

Exact Sciences Corp ( NASDAQ:EXAS) reported a 20% increase in total revenue for Q3 2023, reaching $628 million. The company delivered over a million test results, including a record for Cologuard ...

MADISON, Wis., August 1, 2023 -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $622.1 million for the second quarter ended June 30, 2023, compared to $521.6 million for the same period of 2022.

EXAS is the ticker symbol for Exact Sciences Corporation, a company that provides cancer screening and diagnostic test products. The stock price, news, quote, history and performance outlook of EXAS are shown on Yahoo Finance. See the latest earnings report, analyst report, research reports and more. At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.Estimate Trend. In the past 60 days, the Zacks Consensus Estimate for Exact Sciences’ loss for 2023 has moved 25% north to $2.16. The Zacks Consensus Estimate for 2023 revenues is pegged at $2. ...Complete Exact Sciences Corp. stock information by Barron's. View real-time EXAS stock price and news, along with industry-best analysis.Company profile page for Exact Sciences Corp including stock price, company news, press releases, executives, board members, and contact informationAbout Exact Sciences Corp. ... 2022 and 2021. Stock-based compensation including the incremental fair value of assumed stock awards and accelerated vesting from post-acquisition qualified termination events was zero for the three and six months ended June 30, 2022, compared to $2.4 million and $102.8 million for the three and six months …Exact Sciences Advances Early Cancer Detection and Precision Oncology Programs with Data Presentations at ESMO 2023 Annual Congress. MADISON, Wis. , …Negative. Nikkei 225. 33,451.83. +0.29%. Positive. Source: LSEG - data delayed by at least 15 minutes. Get Exact Sciences Corp (EXAS.A) real-time stock quotes, news, price and financial ...The company's screening revenue (including laboratory services for Cologuard) saw an even more significant growth of 45% year over year. While Exact Sciences remains unprofitable, there was major ...

According to 15 stock analysts, the average 12-month stock price forecast for Exact Sciences stock is $92.07, which predicts an increase of 39.52%. The lowest target is $73 and the highest is $130. On average, analysts rate Exact Sciences stock as a strong buy.Exact Sciences Corporation Common Stock (EXAS) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.MT. Transcript : Exact Sciences Corporation, Q3 2023 Earnings Call, Nov 01, 2023. Nov. 01. CI. Earnings Flash (EXAS) EXACT SCIENCES CORPORATION Reports Q3 Revenue $628.3M, vs. Street Est of $617.2M. Nov. 01. MT. Exact Sciences Corporation Appoints Timothy Scannell as Director and Member of Audit and Finance Committee.Instagram:https://instagram. bug etf stockaffordable dental insurance floridasilver stovklow cost futures broker 09-Oct-2023 ... MADISON, Wis., Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests ... stock c3.aiwhich broker is best for forex trading Nov 30, 2023 · 30,994.67. -0.26%. Negative. Source: LSEG - data delayed by at least 15 minutes. Get Exact Sciences Corp (EXAS.OQ) real-time stock quotes, news, price and financial information from Reuters to ... Transcript : Exact Sciences Corporation, Q3 2023 Earnings Call, Nov 01, 2023. Nov. 01. CI. Earnings Flash (EXAS) EXACT SCIENCES CORPORATION Reports Q3 Revenue $628.3M, vs. Street Est of $617.2M. Nov. 01. MT. Exact Sciences Corporation Raises Revenue Guidance for the Full Year 2023. Nov. 01. is land a good investment The EXACT Sciences Corporation stock price gained 1.49% on the last trading day (Monday, 20th Nov 2023), rising from $66.30 to $67.29. During the last trading day the stock fluctuated 4.45% from a day low at $66.31 to a day high of $69.26. The price has been going up and down for this period, and there has been a 3.21% gain for the last …Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests.